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Abstract
Background: There are no data on the long term use of an artemisinin combination treatment in
moderate or high transmission areas of Africa.
Methods and findings: Artesunate plus amodiaquine (AS+AQ) was used to treat slide-proven
Plasmodium falciparum-infected patients of all ages in the Oussouye district, Casamance, Senegal,
over a period of six years (2000 to 2005). Efficacy, by Kaplan Meier survival analysis (n = 966), and
safety (adverse event rates, n = 752) were determined over 28 days. A weight-based dosing
regimen was used for the loose tablets during 2000–2003 (n = 731) and a commercially available
co-blister was used during 2004–2005 (n = 235).
Annual crude (non PCR corrected) rates remained stable over the study period [range 88.5–96.7%;
overall 94.6 (95% CI 92.9–95.9)]. Nine co-blister treated patients (0.9%) withdrew because of drug-
related adverse events; seven had gastrointestinal complaints of whom two were hospitalized for
vomiting. By Day 28, the mean total bilirubin (n = 72), AST (n = 94) and ALT (n = 95) values
decreased. Three patients had Day 28 AST/ALT values > 40 < 200 IU/L. Changes in white cell
counts were unremarkable (n = 87).
Conclusion: AS+AQ in combination was highly efficacious and well-tolerated in this area and
justifies the decision to use it as first line treatment. Long-term monitoring of safety and efficacy
should continue.
Background
Artemisinin-containing combination therapies (ACTs) are
now being deployed in some 42 malaria endemic coun-
tries and a further 26 have agreed to adopt ACTs following
the World Health Organization (WHO) recommendation
that ACTs should be the first line drugs for treating
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uncomplicated falciparum malaria (data provided by
WHO/GMP, February 2007).
Artesunate plus amodiaquine (AS+AQ) is one of the cur-
rently available ACTs and is in use in Indonesia and 18
African countries (Burundi, Cameroon, Congo, Côte
d'Ivoire, Democratic Republic of Congo, Equatorial
Guinea, Gabon, Ghana, Guinea, Liberia, Madagascar,
Malawi, Mauritania, Senegal, Sao Tome & Principe, Sierra
Leone, Sudan (South), Zanzibar).
Because the WHO policy change is recent, there is, to date,
little experience with the systematic use of these drugs in
malaria endemic countries. The most reliable data regard-
ing systematic use comes from the low transmission areas
of the Thai Burmese border where artesunate plus meflo-
quine has been in continuous use since the early 1990s,
well before the WHO recommendation. This combina-
tion has consistently produced high cure rates, achieved a
reduction in the transmission of Plasmodium falciparum
while the trend of increasing in vitro mefloquine resistance
has been reversed [1,2]. Similar results have been reported
with the deployment of artemether/lumefantrine (Coar-
tem®) in another low-transmission area on the South
Africa-Mozambique border, where the malaria burden
has fallen and where there has been a reduction in mor-
bidity and mortality [3].
By contrast, there are no reported data on the long term
use of ACTs from areas of higher malaria transmission.
Having this information is important because areas of
moderate and high transmission account for most of the
global malaria burden and experience from areas of low
transmission may not necessarily be applied to higher
transmission settings [4]. In addition, the useful therapeu-
tic life spans of the ACTs may vary with transmission
intensity and with such factors like cost, compliance and
treatment seeking behaviour.
This paper reports on the safety and efficacy of AS+AQ in
the chloroquine-resistant, Oussouye district of southern
Casamance, Senegal, during 2000–2005 for treating
patients with parasitologically confirmed falciparum
malaria.
Methods
Study site characteristics
This study was conducted at the outpatient clinics of four
dispensaries (Mlomp, Oussouye, Kabrousse and Djem-
bereng) all situated in the District of Oussouye, southern
Casamance. The total population of the district is circa
70,000, mostly farmers. Malaria transmission is perennial
and meso-endemic with an increase in cases during the
rainy season (July to December). The entomological inoc-
ulation rate is 25 infected bites per person-year [5].
In this area, the rate of chloroquine-resistant strains has
remained stable at around 66% between 1997 and 2004
[6]. Despite this high rate, trials over the past decade have
shown that AQ alone or combined with AS are efficacious
[7-9].
Study methodology
This was a non-comparative assessment of the efficacy and
safety of AS plus AQ conducted over 28 days. Potentially
eligible patients of all ages who attended the clinic with
either a history of fever or a confirmed fever (measured
axillary temperature ≥37.5°C) and a positive Giemsa-
stained thick film for P. falciparum were briefed about the
study and those who gave their written informed consent
were registered and their houses were mapped. Entry cri-
teria included: weight >5 kg; male and non-pregnant or
breast-feeding female; living in the study area (for ease of
follow-up); having given informed consent to participate;
fever or history of fever; falciparum parasitaemia 1,000–
200,000 parasites/µL; no antimalarial drug intake in the
previous week; able to take oral drugs; no signs/symptoms
of severe malaria; no major intercurrent illness or history
of cardiac, hepatic or renal disorder; no known allergy to
study drugs. The study was approved by the Senegalese
National Ethical Committee.
All eligible patients were treated with AS + AQ. Initially
(2000–2001), the use of AS+AQ was restricted to the rainy
season, and later extended (2002–2005) to all year round.
During 2000–2003, loose tablets were used in combina-
tion and patients were dosed by body weight. Subse-
quently a blister pack containing both drugs became
available during 2004–2005 and patients were dosed by
age (except 30 subjects in 2004 who were dosed by
weight). The drugs used were:
▪ loose combination: Arsumax® tablets (Sanofi-Aventis)
containing 50 mg of AS and Camoquin® tablets (Parke-
Davis) containing 200 mg of AQ base tablets. The doses
used were 4 mg/kg/day (AS) and 10 mg/kg/day (AQ) both
for three days.
▪ the blister pack: Arsumax® tablets (Sanofi-Aventis) con-
taining 50 mg of AS and AQ tablets (Sanofi-Aventis) con-
taining 153 mg of AQ base. There were three dosing
blisters and both drugs were administered following the
manufacturer's instructions: (i) children below one year
of age = 1/2 tablet of each drug; (ii) children between one
and six years of age = one tablet of each drug; (iii) children
above six and below 13 years of age = two tablets of each
drug, and (iv) above 13 years of age = four tablets of each
drug.
All treatments were administered under supervision in the
clinic, except in 2005 when only the first dose was super-Malaria Journal 2007, 6:150 http://www.malariajournal.com/content/6/1/150
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vised and patients were instructed to continue their treat-
ment at home. Patients were seen on Days 0–3 inclusive
during 2000–04 (Days 0, 2 and 3 in 2005), and then on
Days 7, 14, 21, 28 or in between, as needed. Non attend-
ees for scheduled clinic visits were actively sought by com-
munity health workers. Giemsa-stained thick films were
read by trained microscopists and confirmed by one of the
investigators (PB).
Study end points
The end point for efficacy was the Day 28 crude cure rate
calculated using Kaplan-Meier survival analysis [10] on
the Intent-to-Treat (ITT) dataset (all patients who entered
the study) for the whole period under study and by year;
the log rank test was used to test for significance between
years. Success was defined as parasite clearance that was
sustained through Day 28. Failure to clear parasites and
recurrent parasitaemia were considered as failures. Geno-
typing parasites was not done to distinguish between
recrudescences and reinfections. All study withdrawals
due to adverse events, irrespective of their relationship to
study drug, were considered as failures. All patients lost to
follow up were censored on the date they were last seen.
Parasitological failures were rescued with quinine.
Safety was assessed by: (i) recording treatment emergent
sign/symptom (TESS, i.e. events which were not present
pre-treatment or worsened with treatment) and (ii) meas-
uring liver (alanine, ALT and aspartic, AST transaminases
and bilirubin), renal functions (creatinine) (KONELAB
60I analyser, Konelab, Finland) and haematology (hae-
matocrit, WBC total counts), aiming for about 30% of the
patients enrolled to have at least one baseline and one
post-treatment sample. The common toxicity criteria for
adverse events (CTCAE Version 3.0 08/09/2006) were
used to evaluate and grade the severity of clinical events
and laboratory measurements. Shift tables were done to
show changes in severity of CTC grades between Day 0
and Day 28.
Data analyses
Data were recorded in a case record form comprising
demography, parasite counts, signs and symptoms, labo-
ratory data and adverse events at each scheduled visit.
They were double keyed in Excel® using an end-user for-
matted sheet with online edit-checks.
Descriptive statistics are presented as counts, percentages,
means and standard deviations, as appropriate. One-way
ANOVA was used to assess the comparability of the
patients' baseline characteristics between years and sites.
Continuous data were assessed for normality using the
Kolmogorov-Smirnov test; if significant, data were log-
transformed and analysed using the 't' test, if normally
distributed. Otherwise the Mann-Witney U test was used
for paired comparisons. Homogeneity of variance was
assessed with the Bartlett test. The Welch adjusted ANOVA
was carried out if variances were unequal. Between groups
comparisons of continuous data were further investigated
with the Tuckey-Kramer post hoc test using means (nor-
mally distributed data) or ranks (skewed data). Dichoto-
mous variables were analysed using chi-squared or
Fisher's exact tests (Freeman-Halton if more than two cat-
egories) test if the expected counts were lower than five in
any cell.
Kaplan-Meier survival analysis was performed to evaluate
cure rates: (i) for all the years combined, (ii) between
years, and (iii) between the loose and the co-blistered
products [10]. The log rank test was used to test for homo-
geneity between survival curves of each year and the loose
and the co-blistered products. A Cox proportional hazard
model of the probability of failure was done to test for the
contribution of the year of treatment and products. A
descending stepwise manual modelling strategy based on
the likelihood ratio test between subsequent models was
carried out, beginning with a saturated model containing
all factors.
A p value of < 0.05 was considered statistically significant.
All tests were two-tailed. Statistical analyses were con-
ducted with the statistical package SAS version 9.3.1 (SAS
Institute, Cary, NC, USA)
Because the dosing of AS and AQ changed during the
study, the doses of AS and AQ taken by patients with the
loose and the blister combinations are presented in rela-
tion to two dosing schedules: (i) the recommended
weight based dosing of 4 mg/kg/d × 3 d for AS and 10 mg/
kg/d × 3 d for AQ base, and (ii) the new age based dosing
regimen with newly defined therapeutic windows of 2–10
and 7.5–15 mg/kg/d, respectively [11].
Results
Baseline characteristics
During 2000–2005, 966 patients were enrolled, of whom
723 in Mlomp (75%), 110 in Diembereng, 27 in Kab-
rousse and 106 in Oussouye. The loose combination was
given to 731 patients during 2000–03 and the co-blistered
product to 235 patients during 2004–05. The dose was
calculated on body weight for 761 patients (731 treated
with the loose and 30 with the co-blistered products) and
on age for 205 (all co-blister). Treatment was given super-
vised to 810 patients and unsupervised to 156 (co-blis-
tered product in 2005). Table 1 shows the patients'
baseline characteristics. Overall, for all the years com-
bined, there were 30% more male than female patients,
the mean age, weight and temperature values were 13.8
years, 33.3 kg and 38.4°C. The geometric mean baseline
parasitaemia was 31,850/µL. The mean (± SD) daily dosesMalaria Journal 2007, 6:150 http://www.malariajournal.com/content/6/1/150
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of AQ and AS for all the study years were 359 (± 179) mg
and 131 (± 66) mg, respectively.
There were significant statistical differences for certain
baseline parameters between most of the years. In partic-
ular, there was a difference in (i) body weight between
2000–2004, 2001–2003, 2001–2004, (ii) AQ dose
between 2000–2004, 2000–2005, 2001–2003, 2001–
2004, 2001–2005, 2002–2004, 2002–2005, and (iii) AS
dose between 2001–2004 and 2004–2005.
The age structure of the population treated is presented in
Figure 1. Overall, 16% of patients were ≤ 5 years of age,
30% were 6–10 years of age, 27% were 11–15 years of age,
11% were 16–20, 8% were 21–30 and 7% ≥ 30 years of
age. Using these categories there was no difference
between years and sites (p > 0.05). Just over half, 57% (n
= 556), of the patients were aged between 6–15 years;
46% (n = 449) were under 11 years of age.
The doses of AS and AQ taken by patients compared with
the weight- and age-based dosing regimens are shown in
Figure 2. With both products used, doses were well within
the newly defined, therapeutic windows for both drugs.
For AS, doses with the loose product and the co-blistered
product were similar and very close to the target dose of 4
mg/day; the co-blister mean doses were slightly lower
with wider 95% CIs. For AQ, doses were higher with both
products than the target dose of 10 mg/day with a tighter
95% CIs for the loose combination except for 11–15 years
old.
Efficacy evaluation
The Kaplan-Meier estimates of the crude cure efficacy rate
was 94.6% (95% CI 93.0; 95.9) for all years combined. By
individual years cure rates were 96.7% [93.2; 98.4] in
2000, 94.0% [90.6; 96.2] in 2001, 95.7% [90.0; 98.2] in
2002, 94.9% [88.2; 97.8] in 2003, 88.5% [79.0; 93.8] in
2004 and 95.9% [91.1; 98.1] in 2005. There were no dif-
ferences (p = 0.12) in cure rates between years by the log
rank test for homogeneity over time (Figure 3) All patients
cleared their parasites by Day 3 (no early treatment fail-
ure, ETF); 36 patients returned with parasites during fol-
low-up (late treatment failures, LTF) and nine were
withdrawn due to an adverse event (considered as failures
in our analysis – see below); 32 were lost to follow-up
(censored) (Table 2). All treatment failures were retreated
successfully with injectable quinine. All 36 LTFs occurred
in patients under 16 years of age (20 in the age range 6–
10). Efficacy was 95% in 0–10 years and 97% in 11 and
above (log rank test, p = 0.03). In 2005 the losses to fol-
low up amounted to 15%, while they were ≤3% in the
other years.
Age structure of the malaria cases treated by year of enrol- ment and mean over 2000–05 Figure 1
Age structure of the malaria cases treated by year of enrol-
ment and mean over 2000–05.
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Table 1: Patient's baseline characteristics overall and by year of enrolment
year 2000 2001 2002 2003 2004 2005 2000–05
Enrolled N 214 302 117 98 79 156 966
Sex ratio F/M 0.6 0.92 0.75 0.69 1.03 0.7 0.77
Age (years) mean 12.8 12.9 14 16.8 15.7 14 13.8
std 9.5 10.5 11.6 14.8 9.8 11.9 11.2
Body weight (kg) mean 31.9 31 33.3 38 38.9 33.8 33.3
std 15.8 16.3 18 20.4 16.6 17.8 17.3
Parasites/µL geomean 32866 48098 24775 24394 39679 17408 31850
std 3.7 3.6 4.8 4.7 3.4 4.7 4.2
Body temp. (°C) mean 38.1 38.7 38.6 38.6 37.8 38.3 38.4
std 1.1 0.6 0.9 1 1.2 1.2 1
AQ dose (mg/d) mean 333 320 351 414 437 399 359
std 156 152 178 242 170 189 179
AS dose (mg/d) mean 128 124 134 140 155 130 131
s t d 6 46 57 17 35 96 26 6Malaria Journal 2007, 6:150 http://www.malariajournal.com/content/6/1/150
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The Kaplan-Meier estimates of the crude cure efficacy rates
were similar (p = 0.14) between the loose (n = 731) and
the co-blistered (n = 235) products: 95.1% (93.3;96.5) vs.
93.1% (88.8;95.8), respectively. This held true whether
dosing was weight (n = 761) or age (n = 205) based:
94.8% (92.9;96.2) vs. 94.2% (89.7;96.7), respectively (p
= 0.51) and whether treatment was supervised (n = 810)
or unsupervised (n = 156): 94.5% (92.7;95.9) vs. 95.9%
(91.1;98.1), respectively (p = 0.75).
Year of study and product used were non significant con-
tributors to failure in a Cox proportional hazard model.
Using a saturated model containing year, product, site,
age, sex, weight, dose AS and dose AQ, the contribution to
hazard of failure was border-line for year (p = 0.06) but
significant for the total daily dose of AS (p = 0.004) for a
hazard of failure of 0.993 [0.988; 0.998]. Only year 2004
was statistically different from the reference year 2000 (p
= 0.003): the hazard of failure was four times greater in
2004 than in 2000 (hazard ratio = 4.496 95% CI = [1.661;
12.168]).
Safety evaluation
Complete safety records are available for 752 patients
enrolled during 2001–2005. At presentation (Day 0), all
patients reported fever or had a measured fever in the
clinic. Other malaria associated symptoms/signs on pres-
entation were weakness [n = 296 (29%)], headache [n =
291 (29%)], vomiting [n = 133 (13%)] and nausea [n =
113 (11%)]. There were no significant differences in the
frequency of symptoms/signs between the different age
groups or sexes.
After treatment, 69 patients (7.1%) experienced at least
one treatment emergent sign/symptom (TESS) which was
either not present pre-treatment or worsened post-treat-
ment: 54 patients suffered one TESS, 14 had two and 1
had three for a total of 85 TESSs: 36 were vomiting, 19 ver-
tigo, 11 asthenia, 8 pruritus without a rash, 5 abdominal
pain, 3 diarrhoea, 2 headaches and 1 nausea (Table 3).
TESSs were more likely to be reported by the co-blister
recipients: 54 (5.6%) vs. 15 (1.5%) (p < 0.0001) and were
independent of age. For the co-blister 39 patients suffered
one TESS during the study, 14 suffered 2 TESSs and one
suffered 3 TESSs; of patients treated with the loose combi-
nation, 15 suffered one TESSs (p < 0.0001).
Nine patients, all treated with the co-blistered product
(two weight-based and seven age-based), were withdrawn
from the study because of a TESS for an overall, crude
withdrawal rate of 0.9%: 3.8% [(co-blister) vs. 0%
(loose), p < 0.0001(Table 4)]. All events were considered
probably related to AS+AQ except one case of vomiting
(possibly related). In five such cases, the daily dose of AQ
exceeded the target dose by 20% or more. Two patients
with Grade 2 vomiting were admitted to hospital for intra-
Mean (95% CI) doses of AS and AQ taken by patients treated with the weight based loose and aged based co-blistered drug  regimens as a function of age Figure 2
Mean (95% CI) doses of AS and AQ taken by patients treated with the weight based loose and aged based co-blistered drug 
regimens as a function of age. a = AS-Loose, b = AS-Blister, c = AQ-Loose, d = AQ-Blister.
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venous quinine and symptomatic treatment; they recov-
ered well. These hospitalizations define these AEs as
serious adverse events (SAEs).
For the laboratory investigations, pretreatment results
were available in 33%, 22% and 17% of patients for hae-
matocrit (Hct), total white blood cells (WBC) and bio-
chemistry, respectively (Table 5). No CTC grade 4 values
were present at baseline and at Day 28. One patient had a
grade 4 creatinine value on Day 7 [16.5 > 6 × ULN, ULN
= 1,20 mg/dL] and returned to grade 0 at Day 28.
There were no shifts between Day 0 and Day 28 from
grades 0 – 2 to grades 3 or 4 (Table 6). Out of 12 changes
in the total WBCs, three patients changed from grade 0 to
grade 1 and one patient from grade 0 to grade 2, while the
remaining eight patients changed to lower grades. There
were 28 changes in CTC grade for AST; four had increased
Kaplan-Meier of one minus survival curves to show cumulative parasitological failure rates overall (2000–05) and by year of  treatment (all ages combined) Figure 3
Kaplan-Meier of one minus survival curves to show cumulative parasitological failure rates overall (2000–05) and by year of 
treatment (all ages combined).
Table 2: Distribution of treatment failures and losses to follow-up by year of study.
(a) by year 2000 2001 2002 2003 2004 2005 2000–05
KM estimate of 
success (95%CI)
96.7 (93.2–98.4) 94 (90.6–96.2) 95.7 (90.0–98.2) 94.9 (88.2–97.8) 88.5 (79.0–93.8) 95.9 (91.1–98.1) 94.6 (93.0–95.9)
LTF withdrawn due to 
AE lost to follow up
7 1 7 2451 3 6
0 0 00459
2 1 3 2 1 23 32
Treatment failures were late parasitological failures [LTF] and withdrawals in the Kaplan-Meier analysis. Losses to follow-up were censored in the 
KM analysis. See KM analysis in figure 3.Malaria Journal 2007, 6:150 http://www.malariajournal.com/content/6/1/150
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grades, from grade 0 to 1 (n = 3) and from grade 0 to grade
2 (n = 1). Out of 29, only two increased shifts were
observed with ALT; one from grade 0 to grade 1 and one
from grade 1 to grade 2. One shift from grade 0 to grade 1
was observed for the serum creatinine. For total bilirubin
there were one change in CTC grades from 0 to 1 and two
from 0 to 2. There were also nine decreases from grade 1
to grade 0 and four decreases from grade 2 to 0.
There were no significant changes in mean values between
Day 0 and Day 28 for the haematocrit (mean diff. 0.31 ±
6.10%, p = 0.51) and total WBC (mean diff. -395 ± 2940,
p = 0.21) but there were significant decrease from Day 0
to Day 7 (2.52 ± 5.56%, p < 0.0001) and increase from
Day 7 to Day 28 (-1.91 ± 4.70%, p < 0.0001) for haemat-
ocrit. The mean AST, ALT and bilirubin decreased signifi-
cantly while there was a small (0.16 mg/dL) but
statistically significant increase in the mean creatinine val-
ues between Day 0 and Day 28 (Figure 4).
Discussion
The favourable results of this study support the policy
decision of using AS+AQ in Senegal. It is premature to
speculate how long this treatment will last but after six
years of use, AS+AQ is still highly effective in the district
of Oussouye where the rate of in vitro chloroquine resist-
ance is > 60% [12]. The patients from this study represent
approximately one third of the more than 3000 patients
who have already received AS+AQ as part of its deploy-
ment as first-line treatment at the district level. Reassur-
ingly, the in vitro susceptibility of P. falciparum parasites to
desethyl-AQ and artemisinin has not changed under drug
pressure during this initial phase of deployment [12].
The efficacy of AS+AQ was well above the 90% threshold
recommended by the WHO despite the conservative
approach used in analysing the data: ITT dataset, adverse
events considered as treatment failures and no adjustment
for PCR proven new infections. As such, this study reflects
more the effectiveness of AS+AQ in the field, while prob-
ably underestimating the real efficacy of this treatment.
Interestingly, failure rates even in children under 10 years
of age were considerably lower than those detected in
1998 in the same age group [7]. It is difficult to explain
these differences; in both cases, 28 day crude, non PCR-
adjusted were measured, while patients were recruited
during the rainy season in 1998 and all year round in
2000–05. Reinfections would be less frequent outside the
rainy seasons; furthermore, the number of malaria cases
has been decreasing after 2000.
Despite the good parasitological efficacy, treatment did
not produce haematological recovery, a softer marker of
efficacy. This may have been due to a combination of a
relatively high mean, pretreatment haematocrit, the nega-
tive effect of AS on reticulocytes, and the short follow up
period. Haematological recovery requires more than four
weeks in some malaria settings [13]. Treatment was well-
tolerated as testified by the very low withdrawal rate
(<1%), including two hospital admissions, because of
drug induced toxicity. No significant clinical laboratory
toxicities were detected.
AS+AQ was equally effective whether given based on body
weight as loose combination or by age as co-blistered
products (as per the manufacturer's instructions); how-
ever, the latter induced more TESS and all the treatment
withdrawals due to intolerance. The use of the co-blister
did result in patients receiving doses of both drugs, in mg/
kg, that were close to the recommended, weight based,
mg/kg dosing regimen, though the co-blistered AQ mg/kg
dose looked to be a little higher than the loose AQ and
had a broader spread of the 95% CIs. Gastrointestinal
complaints accounted for seven of the nine withdrawals
and were probably AQ rather than AS related, given that
AS has excellent tolerability. Five patients received AQ
Table 3: Type, frequency and severity of Treatment Emergent Signs and Symptoms (TESS) and number of patients experiencing at 
least one episode
Symptom Intensity Total n(%) of TESS
Mild Moderate Severe Very severe
Abdominal pain 5 (10.2%) 5 (5.9%)
Asthenia 2 (4.1%) 9 (53%) 11(13%)
Diarrhoea 3 (6.1%) 3 (3.5%)
Headache 1 (2%) 1 (5.9%) 2 (2.4%)
Nausea 1 (33.3%) 1 (1.2%)
Pruritus 4 (8.2%) 3 (17.6%) 1 (33.3%) 8 (9.4%)
Vertigo 4 (25.%) 13 (26.5%) 2 (11.8%) 19 (22.3%)
Vomiting 12 (75%) 21 (42.9%) 2 (11.8%) 1 (33.3%) 36 (42.3%)
Total 16 (18.9%) 49 (57.6%) 17 (20%) 3 (3.5%) 85 (100%)M
a
l
a
r
i
a
 
J
o
u
r
n
a
l
 
2
0
0
7
,
 
6
:
1
5
0
h
t
t
p
:
/
/
w
w
w
.
m
a
l
a
r
i
a
j
o
u
r
n
a
l
.
c
o
m
/
c
o
n
t
e
n
t
/
6
/
1
/
1
5
0
P
a
g
e
 
8
 
o
f
 
1
1
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 4: TESS requiring withdrawal from the study. All patients received the co-blistered product.
Dose (mg/d)
AS AQ
pt# dosed by super vised day withdrawn reason AE (Day = grade) imputability measure taken Age (Years) Weight (Kg) Actual Target Actual Target ∆ %
108 age yes 3 vomiting D0 = 2; D1 = 2; D2 = 1 possible metopimazine i.m. 19 49 200 196 612 490 20%
167 age yes 2 vomiting D1 = 2 probable metopimazine i.m. + quinine i.m. 18 47 200 188 612 470 23%
186 weight yes 2 abdominal pain D1 = 2 probable phloroglucinol p.o+quinine i.m. 19 77 200 308 612 770 -26%
212 weight yes 2 abdominal pain + weakness D1 = 2 probable phloroglucinol p.o+quinine i.m. 14 49 200 196 612 490 20%
266 age no 3 vomiting D1 = 2 probable hospitalized: metopimazine i.v. + quinine i.v. 11 36 100 144 306 360 -18%
464 age no 3 vomiting D1 = 2 probable hospitalized: metopimazine i.v. + quinine i.v. 1 1/2 8.8 50 35.2 153 88 42%
116 age no 2 vomiting D1 = 2 probable metopimazine i.m. + quinine i.m. 18 47 200 188 612 470 23%
8 age no 3 vertigo D1 = 2, D2 = 2 probable none 16 53 200 212 612 530 13%
87 age no 3 pruritus D1 = 2, D2 = 2, D3 = 2 probable dexchlorphe - niramine p.o. 16 59 200 236 612 590 4%
D0 = pre-treatmentMalaria Journal 2007, 6:150 http://www.malariajournal.com/content/6/1/150
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doses ≥20% than the weight based dose of 10 mg/kg and
four were within the 15 mg/kg upper limit of the newly
defined therapeutic window. Never the less, the AQ dose
may have contributed to their gastro-intestinal com-
plaints.
The results obtained when patients are dosed more
loosely by age are important because more practical regi-
mens may expose patients to drug doses that are outside
of the recommended, strictly defined, weight based doses.
A more refined practical dosing has been developed for a
new, aged dosed, fixed dose combination of AS+AQ [14].
It is generally accepted that making treatments easier to
understand and use by patients or e.g. their parents results
in better compliance and that using fixed dose combina-
tions enhances this [15,16]. The AS-AQ fixed-dose combi-
nation will become available later in 2007 and plans are
afoot to test it in Casamance. Its tolerability will be evalu-
ated.
No cases of hepatitis or severe leukopenia (as a surrogate
marker of neutropaenia) were detected, the two amodi-
aquine-associated toxicities that have caused fatalities in
the past, when used as prophylaxis in travelers [16]. How-
ever, the number of closely monitored patients was too
low to detect rare toxicities, and differential WBC counts
could not be done. Intensified monitoring of possible
AS+AQ related AEs needs to be conducted in parallel with
its widespread deployment, a practice which should be
adopted systematically with all other ACTs.
Table 5: Clinical laboratory values on D0 (pre-treatment), Day 7 and Day 28 (mean, standard deviation) and mean (95CI) changes 
between Day 0 and Day 28
Difference vs. D0
N mean std dev N Mean 95% CI Paired t-test
Haematocrit D 0 323 39 6
D 7 233 36.3 5.6 228 -2.5 -3.2 -1.8 <.0001
D 28 171 38.8 5 168 -0.3 -1.2 0.6 0.51
WBCs D 0 212 6421 2929
D 7 120 6746 2509 120 -78.9 -602.6 444.8 0.76
D 28 88 6987 2598 86 395.5 -234.8 1026 0.22
ASAT D 0 167 40.2 38.8
D 7 134 23 41 123 -7.4 -14.4 -0.3 0.04
D 28 106 21 22 101 -15.2 -22.1 -8.3 <.0001
ALAT D 0 169 21.4 16.3
D 7 133 15 29.9 126 -4 -9.2 1.1 0.12
D 28 105 11.7 11.7 103 -9.4 -12.7 -6.2 <.0001
Creatinine D 0 166 0.6 0.3
D 7 132 0.8 1.4 118 0.2 -0.1 0.4 0.23
D 28 106 0.7 0.3 100 0.1 0 0.2 0.02
Bilirubin D 0 156 7 6.2
D 7 123 3.3 2.2 104 -3.9 -5 -2.8 <.0001
D 28 75 4.2 4.3 71 -3.4 -5.1 -1.6 0.0004
D0 = pre-treatment.
std dev = Standard Deviation.
95% CI = Confidence Interval at 95% level for estimated mean change
Table 6: Shift tables of CTC grades from Day 0 to Day 28 by CTC grading
WBC Day 28 ASAT Day 28 ALAT Day 28 Creatinine Day 28 Total Bilirubin Day 28
Day 0 G.0 G. 1 G.2 G.0 G.1 G.2 G.0 G.1 G.2 G.0 G.1 G.0 G.1 G.2
Grade 0 61 3 1 63 3 1 84 1 0 23 1 53 1 2
Grade 1 520 2 0 50 1 7 01 0 0 9 0 0
Grade 2 101540000 0 0 4 0 1
Grade 3 101000
CTC grading: G0 = none; G1 = mild; G2 = moderate; G3 = severe; G4 = very severeMalaria Journal 2007, 6:150 http://www.malariajournal.com/content/6/1/150
Page 10 of 11
(page number not for citation purposes)
This study confirms that, in this area of moderate/intense
transmission, the risk of clinical malaria is present
throughout life and that children between 6–15 years of
age are most affected. This is important as clinical studies
in these areas normally enroll patients up to 10 years old,
and thus would miss an important segment of the patient
population. In this study, although treatment was statisti-
cally less efficacious in children under 11 years of age than
in older patients, efficacy rates were still high in both,
95% and 97%, respectively.
To conclude, this field study has shown a high and stable
cure rate for AS+AQ even when dosed by age. Tolerability
was good but continued intensive safety monitoring is
still required in large numbers of patients for this ACT.
Further research is planned to continue on the AS/AQ
fixed dose combination.
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